OVO Biomanufacturing

Pharmaceuticals
Seed Investment
2020

OVO Biomanufacturing, a spin-out from the University of Warwick and Coventry University, is developing a platform to improve the efficacy of vaccine and gene therapy manufacture.

OVO Biomanufacturing’s technology allows manufacturers of viral vaccines and gene therapies to maximise the production of the target virus used to produce a vaccine or therapy.  Improving the efficacy of manufacture can improve yield, cut lead times and costs and maximise distribution. The resulting increase in availability and affordability of vaccines worldwide is key in the fight against the current and future pandemics.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Nick Wright

view complete team

Contact us

Tel: 01625 344300

email